WHO Drops Hydroxychloroquine, Lopinavir/Ritonavir From Solidarity Trial

The World Health Organization announced on Saturday that it is dropping hydroxychloroquine and lopinavir/ritonavir from its Solidarity Trial after interim results showed neither drug reduces mortality in hospitalized COVID-19 patients compared with standard care. The trials stop with immediate effect; the decision does not affect studies in non-hospitalized patients.

The decision, announced by WHO, ends two of the most closely watched treatment arms in the search for therapies against the pandemic. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients, and it enrolled across multiple countries to test whether existing drugs could be repurposed at scale.

Why the Steering Committee Acted Now

WHO accepted the recommendation of the Solidarity Trial’s International Steering Committee, which weighed the trial’s own interim results against a broader review of evidence from all trials presented at the WHO Summit on COVID-19 research and innovation held on July 1 and 2.

Dr Tedros and Dr Swaminathan on hydroxychloroquine and the Solidarity Trial — World Health Organization (WHO)

The interim results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared with standard of care, according to WHO. Solidarity trial investigators are interrupting the trials with immediate effect.

Hydroxychloroquine and Lopinavir/Ritonavir Arms Stopped in Solidarity Trial

  • Neither hydroxychloroquine nor lopinavir/ritonavir helped hospitalized COVID-19 patients survive at a meaningfully higher rate than standard care.
  • The drugs were not shown to increase deaths in this trial, but laboratory findings from a related trial raised safety concerns that will be published in the peer-reviewed paper.
  • The decision applies only to hospitalized patients in the Solidarity Trial; studies of these drugs in non-hospitalized patients, and as pre- or post-exposure prevention, remain possible.

What the Safety Signals Show

For each of the drugs, the interim results do not provide solid evidence of increased mortality, WHO said. There were, however, some associated safety signals in the clinical laboratory findings of the Discovery trial, an add-on trial participating in the Solidarity Trial.

Those laboratory findings will be reported in the peer-reviewed publication, which is now being readied. Until that publication appears, the detailed numbers behind both the mortality findings and the safety signals remain outside the public record.

How the Drugs Were Supposed to Work

The interim results do not provide solid evidence of increased mortality. Neither mechanism produced a survival benefit in hospitalized patients, according to the interim results. That distinction matters: a drug may fail in late-stage hospitalized patients yet still be evaluated in other settings, which is why WHO framed the discontinuation narrowly.

What This Means for Patients and Regulators

The ruling applies only to the conduct of the Solidarity Trial in hospitalized patients. It does not affect the possible evaluation of hydroxychloroquine or lopinavir/ritonavir in other studies of non-hospitalized patients, or as pre- or post-exposure prophylaxis for COVID-19, WHO said.

Saturday’s decision removes the Solidarity trial platform testing these drugs in hospitalized patients, shrinking the pathway by which a hospitalized patient might receive them as experimental therapy.

Trial arm Drug class Interim mortality vs. standard care Status in Solidarity Trial
Hydroxychloroquine Not specified in sources Little or no reduction Discontinued
Lopinavir/ritonavir Not specified in sources Little or no reduction Discontinued
Standard of care Not specified in sources Comparator Continues

Who Funded the Evidence

The Solidarity Trial is established by WHO, with the add-on Discovery trial contributing the laboratory safety findings now awaiting peer review. The interim results themselves have not yet been published in a peer-reviewed journal; WHO said they are being readied for peer-reviewed publication.

The Question the Peer-Reviewed Paper Must Answer

The discontinuation narrows the therapeutic map for hospitalized COVID-19 patients while leaving the trial’s remaining structure in place. What is not yet known is the full detail behind the findings: the interim Solidarity results are still awaiting peer-reviewed publication, and the laboratory safety signals from the Discovery trial will appear in that same record. Until then, the precise numbers on mortality and the nature of the safety signals remain unreported.

References

  • World Health Organization — statement on the discontinuation of the hydroxychloroquine and lopinavir/ritonavir arms of the Solidarity Trial
  • WHO Summit on COVID-19 research and innovation, July 1–2 — review of evidence from all trials
  • Discovery trial — add-on laboratory findings to be reported in the forthcoming peer-reviewed publication of the Solidarity interim results
Photo of author

Health Desk

Health Desk at Archyde.

Rising Memory Chip Prices and EV Shift Weaken Cobalt Demand